← Evidence map

Observational studyArthritis research & therapy2025

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study.

Andrea Picchianti Diamanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study. | OpenQuestion